Page 842 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

820 Index

Diagnostic imaging DNA binding, 185 Dynamic contrast-enhanced MRI
advances in, 113 DNA-containing virus, 19 Dysgerminomas
(DCE-MRI), 268
DNA damage
types of
VetBooks.ir computed tomography, 115f cellular responses to, 37–40 in cats, 598
cell characteristics in, 599f
magnetic resonance image, 117–118
repair of radiation-induced, 209–210
nuclear scintigraphy, 118 DNA methylation, 269–272 in dogs, 598
PET/CT and/or PET/MR, 118–121 DNMT control of, 269 Dysplasia, 62–63
radiography, 113 DNA methyltransferase-1 (DNMT1) feline, 617
ultrasonography, 113–115 DNA methylation control by, 269 malignant canine mammary neoplasms,
Diagnostic intervention, evaluation of, 93 T-cell lymphoma with trisomy 15, 269 609
DIC. see Disseminated intravascular DNA methyltransferase-1 (DNMT1)
coagulation inhibitor, 269 E
2,4-Dichlorophenoxyacetic acid (2,4-D), types of, 269 E1b-deleted adenovirus, 254, 254f
lymphoma and, 15, 92 DNA repair, errors in, 7 Ear canal tumor
Diet, observational studies for, 87t–91t DNA replication diagnosis of, 360
Differential recall bias, 86 anticancer drugs and, 182 prognostic factors for, 361t
Differentiation errors in, 7 staging for, 361t
control of, 62 DNA synthesis, 182 treatment of, 361
tumor biologic behavior and, 67 DNA vaccine, 375–376 types of
Diffuse large B-cell lymphoma (DLBCL), Docetaxel as benign, 360
153, 700t clinical use of, 195 ceruminous gland adenoma and cysts,
Diffuse nodular dermatofibrosis, 105f pharmacology of, 195 360, 360f
Digital carcinoma, 361–362 DOCP. see Desoxycorticosterone pivalate as malignant, 360
Digital malignant melanoma, 361–362 Dominant gain of function, 42 EBV. see Epstein-Barr virus
survival rate with, 362 Doppler technique, 114–115 Eccrine adenoma, 359–360
treatment of, 362 Dormancy, 55–56 Eccrine carcinoma, 359–360
Digital squamous cell carcinoma vulnerable state and, 55 ECT. see Electrochemotherapy
metastasis of, 362 Dose intensity (DI), 182–183 Ectopic adrenocorticotropic hormone
survival rate with, 362 Dose-limiting toxicity (DLT) (ACTH), 102
Digital tumor definition of, 341–342 tumor associated with, 99b
metastasis of, 362 phase I trial and, 340–341 Effectiveness, 82t
nonneoplastic masses as, 361–362 Doxorubicin (DOX) study, 344–345
signs and breed predilection for, 361 for canine osteosarcoma, 543t Efficacy, 82t
treatment of, 362 clinical use of, 193 research, 344–345
types of, 361–362 embolization and, 178 EGCG. see Epigallocatechin gallate
Digital webbing, malignant melanoma in, for lymphoma, 184 EGFR. see Epidermal growth factor receptor
371f for oral melanoma, 374–375 Ehrlich, Paul, 53
excisional biopsy of, 369f pharmacology of, 192 Electrocautery, biopsies and, 162
Dihydrofolate reductase (DHFR), 185 photodynamic therapy and, Electrochemotherapy (ECT), 170
1,25-dihydroxyvitamin D 3 (calcitriol), for 169–170 Electron, 209
hypoparathyroidism, 581 Doxorubicin-carboplatin alternating Electron microscopy, 74
Direct lymphangiography, 122 chemotherapy, in canine osteosarcoma, “Elimination phase,” of immunoediting
Discrete round cell tumors 543 hypothesis, 231
characteristics of, 141–144 Doxorubicin-carboplatin combined Elion, Gertrude, 182
lymphoma, 142–143 chemotherapy, in canine osteosarcoma, Embolic agent, of interventional oncology, 175
mast cell tumors, 142 542–543 Embolization, of interventional oncology,
mesenchymal/epithelial tumors appearing, Doxorubicin-carboplatin modified 177–179
144 combination sequencing, in canine Embryonal tumors, 658t
plasma cell tumors, 142 osteosarcoma, 543–544 Empathy, expression of, 316
Disseminated intraabdominal tumor, 287t Drainage catheters, of interventional oncology, appointment time, 315
Disseminated intrathoracic tumor, 287t 180 EMT. see Epithelial-to-mesenchymal
Disseminated intravascular coagulation (DIC) Droplet digital PCR, 151–153, 152f transition
cause and effects of, 104 Drug development En bloc resection, 168
incidence of, 104 adaptive trial designs, 346 Endocrine system, tumors of, 565–596
microangiopathic hemolytic anemia and, Food and Drug Administration and, 345 Endocrinologic manifestation, of cancer
103 veterinary registration trials for, 345 acromegaly, 101–102
tumors associated with, 99b, 104 Drug efflux pump, 185 ectopic ACTH, 99b, 102
Disseminated mastocytosis, 383 Drug-eluting beads (DEBs), 178 hypercalcemia of malignancy, 100–101
Distal extremity mast cell tumor, 388 Drug therapy of cancer, toxicities associated hyperestrogenism, 101
DLBCL. see Diffuse large B-cell lymphoma with, 186–188 hypoglycemia, 99b, 101
DLT. see Dose-limiting toxicity DSMB. see Data Safety and Monitoring Board Endogenous/exogenous sex hormone,
DNA. see Deoxyribonucleic acid DVCR. see Danish Veterinary Cancer Registry observational studies for, 87t–91t